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bjectives The aim of this study was to assess the risk-beneﬁt of enoxaparin (Sanoﬁ-Aventis, Paris,
rance) in primary percutaneous coronary intervention (PCI).
ackground Randomized studies have demonstrated the superiority of enoxaparin over unfractionated
eparin (UFH) in acute ST-segment elevation myocardial infarction (STEMI) treated with ﬁbrinolytics.
ethods In the FINESSE (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)
rial—a double-blind, placebo-controlled study—2,452 patients with STEMI were randomized to primary
CI or facilitated PCI with abciximab alone or with half-dose reteplase. In this prospective FINESSE sub-
tudy, centers pre-speciﬁed use of either enoxaparin (0.5 mg/kg intravenous [IV], 0.3 mg/kg subcutane-
us [SC]) or UFH (40 U/kg IV, 3,000 U maximum) with PCI. A logistic-regression model and a propensity
ultivariate model, both adjusted for baseline variables, were used to evaluate primary safety and sec-
ndary efﬁcacy end points for enoxaparin versus UFH.
esults Enoxaparin was administered to 759 patients and UFH to 1,693 patients. Nonintracranial
hrombolysis In Myocardial Infarction (TIMI) major/minor bleeding was not signiﬁcantly different, but
ower nonintracranial TIMI major bleeding was found with enoxaparin (2.6% vs. UFH 4.4%, logistic-regres-
ion adjusted odds ratio [OR]: 0.55; 95% conﬁdence interval [CI]: 0.31 to 0.99, p  0.045), whereas intra-
ranial hemorrhage was similar (0.27% vs. 0.24%, adjusted OR: 1.03; 95% CI: 0.11 to 9.68, p  0.980).
ower death, myocardial infarction, urgent revascularization, or refractory ischemia through 30 days was
lso associated with enoxaparin (5.3%) versus UFH (8.0%, adjusted OR: 0.47, 95% CI: 0.31 to 0.72, p 
.0005) as was all-cause mortality through 90 days (3.8% vs. 5.6%, respectively, adjusted OR: 0.59, 95% CI:
.35 to 0.99, p  0.046). End points evaluating the net clinical beneﬁt also signiﬁcantly favored enoxapa-
in over UFH.
onclusions Enoxaparin seems to be associated with a lower risk of cardiovascular outcomes compared
ith UFH in patients with STEMI undergoing primary PCI. Conﬁrmation of these ﬁndings in a random-
zed study is warranted. (A Study of Abciximab and Reteplase When Administered Prior to Catheteriza-
ion After a Myocardial Infarction [Finesse]; NCT00046228) (J Am Coll Cardiol Intv 2010;3:203–12)
2010 by the American College of Cardiology Foundation
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The FINESSE Enoxaparin Substudy
204n primary percutaneous coronary intervention (PCI) of acute
T-segment elevation myocardial infarction (STEMI), un-
ractionated heparin (UFH) is the only recommended antico-
gulant drug, despite having a “C” level of evidence and no
tandardized dosing aside from rules extended from elective
ngioplasty (1–3). Compared with UFH, enoxaparin (Sanofi-
ventis, Paris, France) has a more stable and predictable
See page 213
nticoagulant dose-response, eliminating the need for coagu-
ation monitoring; a lower binding affinity for plasma and
issue proteins; and a higher ratio of anti-Xa to anti-IIa,
esulting in less thrombin generation and activation. Enoxapa-
in also reduces platelet activation, von Willebrand factor
elease, and inflammation (4–6).
Intravenous enoxaparin has been
compared with IV UFH in 13 ran-
domized studies of elective PCI. In
the largest study of 3,528 patients,
enoxaparin (0.5 mg/kg) signifi-
cantly reduced the primary safety
end point of any bleeding, with a
57% reduction in major bleeding,
compared with an activated clotting
time (ACT)-adjusted UFH regi-
men (7). Although underpowered
for efficacy, 30-day ischemic events
were not statistically different in the
enoxaparin and UFH groups. A
recent meta-analysis of all random-
ized studies performed in PCI (n
7,318) confirmed the significant re-
duction of major bleeding with
enoxaparin and showed, with an
adequate power, identical ischemic
event rates for patients treated with
UFH or enoxaparin (8).
Enoxaparin has also been investigated as a heparin
ubstitute in STEMI but almost exclusively in the context of
rom the *Pitiè-Salpêtrière University Hospital, Paris, France; †Cleveland Clinic
oundation, Cleveland, Ohio; ‡The James Cook University Hospital, Middles-
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bbreviations
nd Acronyms
CT  activated clotting
ime
MI  body mass index
I  confidence interval
CG  electrocardiogram
V  intravenous
I  myocardial infarction
R  odds ratio
CI  percutaneous
oronary intervention
C  subcutaneous
FH  unfractionated
eparin
TEMI  ST-segment
levation myocardial
nfarction
IMI  Thrombolysis In
yocardial Infarctionania, and Eli Lilly, Indianapolis, Indiana. Dr. Montalescot reports receiving
M
abrinolysis. In the large ExTRACT (Enoxaparin and
hrombosis Reperfusion for Acute Myocardial Infarction
reatment) trial, treatment with subcutaneous enoxaparin
hroughout the index hospital stay period was superior to
reatment with UFH for at least 48 h in reducing death or
ecurrent myocardial infarction (MI) but was associated
ith increased major bleeding episodes (9). A recent meta-
nalysis of enoxaparin in acute coronary syndromes demon-
trated that the increased risk for bleeding was offset by the
eduction in death or MI and that the net benefit was
ignificantly greater with enoxaparin than UFH (10).
Although there is evidence for the superiority of enox-
parin in STEMI treated with fibrinolytics, investigation of
noxaparin in primary PCI of acute STEMI is limited to
mall observational studies or series of patients (11,12). A
arger experience with enoxaparin in combination with
gents commonly used in acute MI is needed to fully assess
he efficacy and safety of enoxaparin in primary PCI of acute
TEMI.
The recent multicenter, randomized, double-blind,
lacebo-controlled FINESSE (Facilitated INtervention with
nhanced Reperfusion Speed to Stop Events) trial compared
he efficacy of facilitated PCI with abciximab alone or in
ombination with reteplase versus primary PCI with in-
aboratory abciximab in 2,452 patients with acute STEMI.
acilitation with abciximab alone or combined with half-dose
eteplase increased major hemorrhage and did not demonstrate
ignificant reduction in the 90-day primary end point of
omposite all-cause mortality or complications of MI (ventric-
lar fibrillation beyond 48 h, cardiogenic shock, and congestive
eart failure requiring repeat hospital stay or emergency room
isit) (13). In this prospective, nonrandomized, stratified
INESSE substudy, we obtained clinical data on the safety and
fficacy of enoxaparin versus UFH as the sole background anti-
hrombin therapy in conjunction with 3 different randomized
trategies assessing the value of pharmacologic facilitation before
rimary PCI for STEMI. Additionally, we used 2 adjusted
nalyses to explore the robustness of the differences in clinical
utcomes in all patients treated with enoxaparin versus UFH.
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205ethods
atients. Details of the FINESSE trial design and primary
utcome have been previously reported (13,14). Briefly,
atients presenting within 6 h of symptom onset with ST-
egment elevation or new left bundle branch block were
nrolled if the estimated time to diagnostic catheterization was
to 4 h from randomization and if they were not at low risk
i.e., inferior infarction and age 60 years). Patients who
eceived any UFH within 24 h of randomization or who had a
istory of allergy to enoxaparin or who had an estimated
reatinine clearance 30 ml/min adjusted for sex were ex-
luded from the enoxaparin substudy. However, there was no
ose adjustment protocol of enoxaparin for renal function.
tudy design. In the FINESSE trial, patients were ran-
omly allocated to combination-facilitated PCI (abciximab
Centocor B.V., Leiden, the Netherlands] 0.25 mg/kg IV
olus  reteplase [Centocor B.V.] 2 5-U boluses separated
y 30 min for those 75 years of age or 1 5-U bolus for
hose 75 years of age), abciximab-facilitated PCI (0.25
g/kg IV bolus), or primary PCI (placebo with blinded
rossover therapy to abciximab 0.25 mg/kg IV bolus imme-
iately before PCI). After PCI, all patients were maintained
n abciximab 0.125 g/kg/min IV (maximum 10 g/min)
or 12 h. All patients were to have received aspirin 81 to 325
g orally (or 250 to 500 mg IV, depending on approval per
ountry) as soon as possible after randomization and daily
or at least 90 days after randomization.
In this FINESSE enoxaparin substudy, randomized pa-
ients were stratified by study center to receive enoxaparin or
FH. Each study center pre-specified its choice of adjunct
nti-thrombin therapy as either UFH (40 U/kg, 3,000 U
aximum; 200 to 250 s target ACT) or weight-adjusted
noxaparin (0.5 mg/kg IV and 0.3 mg/kg SC; no target
CT). Additional UFH for PCI was not permitted in the
atheterization laboratory for patients stratified to receive
noxaparin. Enoxaparin was not allowed within 24 h of
andomization for patients stratified to receive UFH. Ad-
itional enoxaparin or UFH was permitted 24 h after
andomization for any patient with an indication for longer-
erm anticoagulation. The primary safety end points were: 1)
he incidence of nonintracranial Thrombolysis In Myocardial
nfarction (TIMI) bleeding (major or minor); and 2) the
ncidence of intracranial hemorrhage (including hemorrhagic
ransformation) through discharge or day 7, whichever was
arlier. The secondary efficacy end points were: 1) the
INESSE main study primary end point (all-cause mortality or
omplications of MI) through 90 days; 2) complications of MI
hrough 90 days; and 3) all-cause mortality through 90 days.
ost-hoc exploratory analyses. Because many primary PCI
rials have used 30-day ischemic end points and to fully
xplore the difference between enoxaparin and UFH therapy
n thrombotic events in the setting of primary PCI for
TEMI, additional classical ischemic end points (death, de-infarction, stroke, urgent revascularization, refractory
schemia) through 30 days were explored. Net clinical benefit
nd points combining efficacy outcomes through 90 days and
IMI major bleeding through discharge/day 7 were also
valuated. Because the comparison was not randomized, 2
ifferent approaches correcting for baseline differences were
sed to explore the enoxaparin and UFH subpopulations.
The protocol was approved by the institutional review
oard or independent ethics committee for each study
enter, and all patients provided written informed consent.
tatistical analysis. Descriptive statistics were used where
ppropriate to evaluate the safety and efficacy of enoxaparin
ersus UFH. The difference in baseline characteristics between
noxaparin and UFH was tested with the Wilcoxon test for
ontinuous variables and the chi-square test for categorical
ariables. Safety analyses were performed according to ran-
omized PCI strategy (combination-facilitated, abciximab-
acilitated, or primary) and nonrandomized adjunct anti-
hrombin therapy (enoxaparin or UFH). Efficacy analyses were
erformed comparing enoxaparin with UFH irrespective of
andomized PCI strategy (intent-to-treat). No formal statisti-
al testing was performed for enoxaparin versus UFH within
ach PCI strategy, but testing for heterogeneity was
erformed.
To adjust for multiple risk factors and potential imbal-
nce of other factors between the 2 subpopulations, logistic
egression modeling was first used. For verification, a
ropensity score methodology was then used. Two sets of
ariables were considered in each of the statistical ap-
roaches. The first set was pre-selected before the modeling
xercise, and it consisted of age, sex, Killip class (1 vs. 1),
nterior MI (Y/N), prior MI (Y/N), hypertension (Y/N),
eographic region (Western Europe, Eastern Europe, North
merica/rest of the world) and hub/spoke (i.e., PCI-
apable/not), randomized PCI strategy, time from symptom
nset to electrocardiogram (ECG) (taken during the first
edical contact [e.g., in the ambulance, spoke hospital]), and
ime from ECG to balloon. These items were chosen because
hey are known risk factors, site-related factors (sites selected
noxaparin or UFH strategy), or treatment-related factors. The
econd set consisted of the variables that had a statistically
ignificant difference (p 0.05) between enoxaparin and UFH
n baseline demographic data, medical history, or medication
eceived at baseline (Table 1).
The logistic regression model included all variables in the
rst set, and then the final model was determined by
nvestigating whether adding demographic variables, med-
cal history-related variables, or medication-related variables
n the second set improved the model fitting. The criterion
sed for model fitting is Akaike’s information criterion (15)
ith respect to predicting 90-day mortality. When demo-
raphic, medical history, or medication variables were added
o the model including the first set of variables, only the
emographic variables body mass index (BMI) and smoking
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206Table 1. Baseline Characteristics and Concomitant Medications From Randomization Through Day 7
Variable UFH (n  1,693) Enoxaparin (n  759) p Value
Pre-selected
Age (yrs) 63.0 63.0 0.331
Sex (% female) 438 (25.9) 204 (26.9) 0.600
Prior myocardial infarction 194 (11.5) 72 (9.5) 0.146
Anterior myocardial infarction 802 (47.4) 371 (48.9) 0.489
Killip class 1 1,513 (89.4) 655 (86.3) 0.0281
Hypertension or treated for hypertension 875 (51.7) 298 (39.3) 0.0001
Hub 1,037 (61.3) 431 (56.8) 0.037
Region 0.0001
Eastern Europe 977 (57.7) 101 (13.3)
Western Europe 531 (31.4) 625 (82.4)
North America/rest of the world 185 (10.9) 33 (4.3)
Symptom onset to electrocardiogram (h) 2.2 1.9 0.0001
Electrocardiogram to balloon (h) 2.3 2.1 0.0001
Randomized percutaneous coronary intervention strategy 0.949
Primary 560 (33.1) 246 (32.4)
Abciximab-facilitated 563 (33.3) 255 (33.6)
Combination-facilitated 570 (33.7) 258 (34.0)
Variables signiﬁcantly different between the UFH and enoxaparin subpopulations
Body mass index (kg/m2) 26.9 26.3 0.0007
Smoker 1,081 (63.9) 529 (69.7) 0.0048
Diabetes 286 (16.9) 94 (12.4) 0.0043
Chronic lung disease 103 (6.1) 68 (9.0) 0.0098
Other characteristics
Medical history
Prior transient ischemic attack 29 (1.7) 15 (2.0) 0.650
Prior stroke 31 (1.8) 14 (1.8) 0.982
Prior coronary artery bypass graft 29 (1.7) 13 (1.7) 1.000
Prior percutaneous coronary intervention 91 (5.4) 43 (5.7) 0.770
Previous congestive heart failure 28 (1.7) 6 (0.8) 0.091
Peak activated clotting time(s) 230 132 0.0001
Cardiac medications at baseline*
Aspirin 1,290 (76.2) 461 (60.7) 0.0001
Ticlopidine/clopidogrel 141 (8.3) 126 (16.6) 0.0001
Nitrates 841 (49.7) 319 (42.0) 0.0005
Diuretics 162 (9.6) 93 (12.3) 0.0441
Gastric protective 305 (18.0) 69 (9.1) 0.0001
Medications after baseline
Randomization through 24 h after randomization
Aspirin 1,581 (93.4) 716 (94.3) 0.371
Ticlopidine/clopidogrel 1,494 (88.2) 692 (91.2) 0.031
24 h after randomization through discharge/day 7
Aspirin 1,600 (94.5) 731 (96.3) 0.057
Ticlopidine/clopidogrel 1,531 (90.4) 692 (91.2) 0.560
Any enoxaparin 308 (18.2) 229 (30.2) 0.001
Any enoxaparin treatment through discharge/day 7 342 (20.2) 745 (98.2)
Any UFH treatment through discharge/day 7 1,656 (97.8%) 36 (4.7%)
Duration of enoxaparin treatment in enoxaparin-treated patients through
discharge/day 7, days
3 (2–5) 1 (1–4)
Any enoxaparin treatment from discharge/day 7 to day 90 69 (4.1) 85 (11.2) 0.001
Values are median, n (%), or median (interquartile range). Baseline characteristics were analyzed with the chi-square test for the discrete variables and the Wilcoxon test for the continuous variables. *From 7
days before randomization to randomization.UFH unfractionated heparin.
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207tatus improved the model fitting for 90-day mortality.
herefore, the adjusted safety and efficacy analysis results
hown in the following text were based on the final model,
hich included covariates of the first set of variables and
MI and smoking status.
The second approach developed to verify the results of
he first model was an analysis based on propensity scores
16). The propensity score of receiving enoxaparin, the
robability of receiving enoxaparin, was estimated for each
atient by the logistic regression model with covariates of
oth sets of the aforementioned variables. Then patients
ere stratified by the quintiles of the estimated propensity
cores and were analyzed with the Cochran-Mantel-Haenszel
ethod, stratified by the quintiles of the propensity score and
eographic region. Because the geographic region was not
dequately balanced by the quintiles of the estimated propen-
ity score, the region was excluded for the propensity model
nd was adjusted independently from the propensity score.
Adjusted odds ratios (ORs), confidence intervals (CIs),
nd p values reported in the article are from the logistic
egression model unless noted otherwise. No adjustments
ere made for multiple comparisons. The authors had
ull access to the data and take responsibility for its
ntegrity. All authors have read and agree to the manu-
cript as written.
esults
opulation characteristics. Of the 2,452 patients in the
INESSE trial, 759 (U.S. n  33, Europe n  726) were
nrolled in the enoxaparin substudy and 1,693 received
FH. Study centers in 8 countries pre-specified the use of
noxaparin (Table 1). In the enoxaparin subpopulation,
ignificantly greater proportions of patients were enrolled in
estern Europe (vs. Eastern Europe or North America/rest
f the world), were smokers, had Killip class 1, or had
hronic lung disease (Table 1). In the UFH subpopulation,
edian BMI was higher, the median times from symptom
nset to ECG or from ECG to balloon were longer, and a
ignificantly greater proportions of patients were enrolled at
ub sites or had hypertension or diabetes. The distribution
f TIMI risk score was similar across UFH and enoxaparin
roups (TIMI risk score 5: 9.8% enoxaparin vs. 10.6%
FH, p  0.51). Concomitant medication use at baseline
nd after randomization had some differences between
FH and enoxaparin groups (Table 1).
The recommended maximum bolus dose of 3,000 U of
FH was lower than that of many prior studies, although
dditional heparin was recommended before PCI to main-
ain the ACT at 200 to 250 s, which was achieved in
pproximately 40% and which was 250 s in approximately
7% in those in whom it was measured. Relatively few
atients received additional heparin during the PCI in the
FH group (n  86) with a median dose of 2,545 U. The 0edian cumulative dose (IV and SC) of enoxaparin during
he hospital stay was 70 mg.
There were 170 centers that were pre-specified to admin-
ster UFH and 42 centers pre-specified to administer
noxaparin as the primary antithrombin. Of the 759 pa-
ients enrolled at hospitals that chose to administer enox-
parin, 93.4% actually received at least 1 dose within the
rst 24 h after randomization, whereas 18 (2.4%) also
eceived UFH in this period. Of the 1,698 patients enrolled
t hospitals that chose to administer UFH, 91.4% received
t least 1 dose of UFH within 24 h after randomization,
hereas 67 (3.9%) also received enoxaparin in this period.
afety. Nonintracranial TIMI major bleeding was signifi-
antly lower in patients who received enoxaparin (2.6%)
ersus UFH (4.4%; adjusted OR: 0.55; 95% CI: 0.31 to
.99, p  0.045) (Fig. 1, Table 2). However, nonintracra-
ial TIMI minor bleeding was significantly more frequent
ith enoxaparin, resulting in similar rates of nonintracranial
ajor or minor bleeding in the 2 groups (adjusted OR: 1.17;
5% CI: 0.85 to 1.63, p  0.334) (Fig. 1). No interaction
as observed between PCI strategy and either nonintracra-
ial TIMI major bleeding (p  0.296) or major or minor
leeding (p 0.811). Intracranial hemorrhage occurred in 6
atients overall (all in patients75 years of age), 5 of whom
ere randomized to combination-facilitated PCI. The fre-
uency of intracranial hemorrhage was similar across the
noxaparin and UFH groups (0.27% vs. 0.24%, adjusted
R: 1.03, 95% CI: 0.11 to 9.68, p  0.980). Results from
he propensity-adjusted model were generally consistent
ith those from the logistic regression-adjusted model.
Several sensitivity analyses were performed to evaluate
opulations previously identified to be at increased risk of
leeding. Patients who received both enoxaparin and UFH
ithin 24 h after randomization tended, although infre-
uently, to have higher rates of bleeding than those receiv-
ng only 1 antithrombin (data not shown). For patients 75
ears of age or older, although overall bleeding rates were
igher than those in younger patients for all categories
valuated, bleeding rates tended to be lower with enoxaparin
han with UFH (e.g., nonintracranial TIMI major or minor
leeding 11.7% vs. 20.1%, p  0.067).
fﬁcacy. The FINESSE 90-day primary end point of com-
osite all-cause mortality or complications of MI (ventric-
lar fibrillation beyond 48 h, cardiogenic shock, and con-
estive heart failure requiring repeat hospital stay or
mergency room visit) occurred in 9.6% of patients who
eceived enoxaparin and 10.6% of patients who received
FH (p  0.45) (Table 3). After adjustment for baseline
ariables, a trend for lower risk of reaching the primary end
oint was associated with enoxaparin use (adjusted OR:
.73; 95% CI: 0.52 to 1.03, p  0.075). Complications of
I through 90 days tended to be lower with enoxaparin
ersus UFH (7.1% vs. 8.3%; adjusted OR: 0.70; 95% CI:
.47 to 1.02, p  0.066). A lower risk of all-cause
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208ortality at 90 days was associated with enoxaparin
ompared with UFH (3.8% vs. 5.6%; adjusted OR: 0.59;
5% CI: 0.35 to 0.99, p  0.046) that was more
ronounced in the primary PCI group (Fig. 2); however,
test for interaction across the 3 PCI strategies was not
ignificant (p  0.285). Results from the propensity-
djusted model were generally consistent with those from
he logistic regression-adjusted model.
Death or reinfarction through 30 days was less frequent
ith enoxaparin compared with UFH (4.0% vs. 5.6%, adjusted
R: 0.58; 95% CI: 0.35 to 0.96, p  0.036), as was the
omposite of death, reinfarction, urgent revascularization, or
Figure 1. Primary Safety End Points Through Discharge or Day 7
*Interaction p value among the 3 percutaneous coronary intervention (PCI) strateg
Infarction; UFH  unfractionated heparin.
Table 2. Safety
Crude
Outcome
Enoxaparin
(n  740)
UFH
(n  1,674) OR (9
Nonintracranial TIMI major or minor
bleeding through discharge/day 7
89 (12.0%) 165 (9.9%) 1.25 (0
Nonintracranial TIMI major bleeding
through discharge/day 7
19 (2.6%) 74 (4.4%) 0.57 (0
TIMI minor bleeding through
discharge/day 7
70 (9.5%) 91 (5.4%) 1.82 (1
Intracranial hemorrhage through
discharge/day 7
2 (0.27%) 4 (0.24%) 1.13 (0CI confidence interval; OR odds ratio; TIMI thrombolysis in myocardial infarction; UFH unfractionefractory ischemia through 30 days (5.3% vs. 8.0%, adjusted
R: 0.47; 95% CI: 0.31 to 0.72, p  0.0005) (Fig. 2).
et adverse clinical outcome. The composite of death, MI,
rgent revascularization, or stroke through 90 days or major
leeding through discharge/day 7 occurred in 8.2% of
atients treated with enoxaparin versus 11.7% of patients
reated with UFH (crude p  0.009) (Table 3). This
.5% absolute reduction with enoxaparin was consistent
cross all 3 PCI strategies (adjusted OR: 0.64; 95% CI:
.45 to 0.91, p  0.013). Similarly, the composite of
eath, MI, or stroke through 90 days or major bleeding
hrough discharge/day 7 was lower in patients treated
 conﬁdence interval; OR  odds ratio; TIMI  Thrombolysis In Myocardial
Adjusted
(Logistic Regression) Propensity-Adjusted
) p Value OR (95% CI) p Value OR (95% CI) p Value
4) 0.1096 1.17 (0.85–1.63) 0.3338 1.05 (0.79–1.54) 0.5676
5) 0.0312 0.55 (0.31–0.99) 0.0451 0.52 (0.28–0.95) 0.0417
1) 0.0003 1.68 (1.14–2.47) 0.0089 1.57 (1.06–2.34) 0.0292
9) 0.887 1.03 (0.11–9.68) 0.9804 1.17 (0.15–9.36) 0.8941ies. CI5% CI
.95–1.6
.34–0.9
.31–2.5
.21–6.1ated heparin.
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209ith enoxaparin versus UFH (7.8% vs. 11.2%, crude p 
.009; adjusted OR: 0.61; 95% CI: 0.43 to 0.88, p 
.009). The composite of death, MI, urgent revascular-
zation, or recurrent ischemia through day 30 or any
IMI major or TIMI minor bleeding through discharge/
ay 7 was similar in the enoxaparin and the UFH groups
16.5% vs. 16.4%, crude p  0.9761).
iscussion
ur findings suggest a lower risk of TIMI major bleeding and
schemic end points as well as all-cause mortality with the use
f enoxaparin compared with standard UFH in primary PCI of
TEMI. The main limitation of this substudy was the non-
andomized nature of the comparisons. However, the use of 2
ifferent statistical models (logistic regression and propensity
nalysis) to adjust for baseline imbalances in the groups helps
o support the robustness of these findings.
Presently, UFH has not been officially approved for use in
Table 3. Efficacy
Crude
Outcome
Enoxaparin
(n  759)
UFH
(n  1,693) OR (
FINESSE primary composite end point
(all-cause mortality or
complications of myocardial
infarction) through 90 days
73 (9.6%) 180 (10.6%) 0.89 (0
All-cause mortality through 90 days 29 (3.8%) 95 (5.6%) 0.67 (0
Complications of myocardial
infarction through 90 days
54 (7.1%) 140 (8.3%) 0.85 (0
Death or myocardial infarction
through 30 days
30 (4.0%) 94 (5.6%) 0.70 (0
Death, myocardial infarction, or
urgent revascularization through
30 days
33 (4.4%) 101 (6.0%) 0.72 (0
Death, myocardial infarction, urgent
revascularization or refractory
ischemia through 30 days
40 (5.3%) 135 (8.0%) 0.64 (0
Death, myocardial infarction, or
stroke through 30 days
35 (4.6%) 103 (6.1%) 0.75 (0
Death, myocardial infarction, urgent
revascularization, or stroke through
90 days or major bleeding through
discharge/day 7
62 (8.2%) 198 (11.7%) 0.67 (0
Death, myocardial infarction, or
stroke through 90 days or major
bleeding through discharge/day 7
59 (7.8%) 190 (11.2%) 0.67 (0
Death, myocardial infarction, stroke,
TIMI major bleed (including ICH)
through discharge/day 7
42 (5.5%) 140 (8.3%) 0.65 (0
Death, myocardial infarction, urgent
revascularization, TIMI major bleed
(including ICH) through discharge/
day 7
40 (5.3%) 137 (8.1%) 0.63 (0
FINESSE Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events trial; ICH inCI, and no placebo-controlled trials of UFH have been sonducted in this indication. The optimal UFH dosing and/or
CT targets remain uncertain. Guidelines from the American
ollege of Cardiology, the American Heart Association, the
uropean Society of Cardiology, and the American College of
hest Physicians recommend 3 alternative ACT target levels
epending on the type of measurement device and the con-
omitant use of glycoprotein IIb/IIIa inhibitors (1–3). Several
tudies and meta-analyses have reported conflicting results for
he utility of these recommendations (17,18).
Lower molecular weight heparin has a more predictable
nticoagulant activity compared with UFH. The intrave-
ous use of enoxaparin affects immediate anticoagulation,
ith anti-Xa levels0.5 IU/ml for 2 h; rapid clearance; and
pharmacokinetic profile well-suited for PCI (19). In the
arge, randomized STEEPLE (SafeTy and Efficacy of
noxaparin in PCI patients, an internationaL randomized
valuation) trial, IV enoxaparin 0.5 mg/kg demonstrated a
etter safety profile than IV UFH in elective PCI, with a
Adjusted
(Logistic Regression) Propensity-Adjusted
I) p Value OR (95% CI) p Value OR (95% CI) p Value
19) 0.4456 0.73 (0.52–1.03) 0.0749 0.75 (0.53–1.05) 0.1062
02) 0.0630 0.59 (0.35–0.99) 0.0462 0.64 (0.39–1.04) 0.0660
18) 0.3279 0.70 (0.47–1.02) 0.0660 0.70 (0.47–1.04) 0.0883
07) 0.0965 0.58 (0.35–0.96) 0.0356 0.58 (0.35–0.95) 0.0332
07) 0.1049 0.63 (0.39–1.03) 0.0630 0.62 (0.39–1.00) 0.0561
92) 0.0170 0.47 (0.31–0.72) 0.0005 0.52 (0.34–0.78) 0.0012
11) 0.1450 0.62 (0.39–1.00) 0.0478 0.63 (0.40–1.01) 0.0604
91) 0.0091 0.64 (0.45–0.91) 0.0134 0.64 (0.45–0.90) 0.0129
91) 0.0093 0.61 (0.43–0.88) 0.0085 0.57 (0.39–0.84) 0.0060
93) 0.0176 0.57 (0.38–0.88) 0.0129 0.56 (0.37–0.85) 0.0064
91) 0.0132 0.57 (0.37–0.87) 0.0122 0.56 (0.37–0.86) 0.0081
al hemorrhage; other abbreviations as in Table 2.95% C
.67–1.
.44–1.
.61–1.
.46–1.
.48–1.
.45–0.
.50–1.
.50–0.
.49–0.
.46–0.
.44–0.ignificant reduction of major bleeding and similar efficacy.
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210he STEEPLE results were recently confirmed in a global
eta-analysis of 13 randomized studies reporting a 43%
eduction of major bleeding and similar ischemic event rates
ith lower molecular weight heparin (7,8). Similarly, in
he present enoxaparin substudy of the FINESSE study,
he same IV regimen of 0.5 mg/kg enoxaparin provided a
5% relative risk reduction of major bleeding in all
atients who received abciximab. This benefit of enox-
parin was observed in comparison with a dose of 40
U/kg of UFH, a dose much lower than in any of the
revious randomized studies.
In our enoxaparin substudy, enoxaparin use was associ-
ted with a lower risk of all ischemic end points compared
ith UFH. The observed 30% lower relative risk in death or
I through 30 days is comparable to the 23% risk reduction
n the same end point observed in the randomized
xTRACT-PCI study and the 31% reduction recorded in
he ACOS (Acute Coronary Syndromes) registry, both
erformed in STEMI patients (20,21); other studies evalu-
ting enoxaparin in mechanical reperfusion of STEMI were
oo small to evaluate clinical outcomes (22,23). The
xTRACT-PCI patients, who underwent PCI approximately
days after thrombolysis of STEMI, were possibly at lower
isk for periprocedural complications than FINESSE patients,
ho underwent primary PCI approximately 2 h after presen-
ation. Our adjusted multivariable analyses demonstrate a
ower risk in the double end point of death or MI and an
pproximately one-third reduction in the incidence of the
Figure 2. Secondary Efficacy End Points Through 30 and 90 Days
*Interaction p value among the 3 PCI strategies. Abbreviations as in Figure 1.omposite ischemic end point including urgent revascular- ization and refractory ischemia (p  0.0005). Regional
ifferences in revascularization strategies, some of which
ere not adjusted for, could have confounded some of these
esults. All-cause mortality also seemed to be lower with
noxaparin than with UFH. This is an interesting finding,
iven that only bivalirudin (vs. UFH  glycoprotein IIb/
IIa inhibitors) and abciximab (vs. placebo) have been
ssociated with a survival benefit in primary PCI (24–26)
nd that all patients in this study were to have received
bciximab. A similar trend was observed for mortality in
he recent meta-analysis of the enoxaparin trials of
TEMI reperfused with thrombolysis (OR: 0.92, 95%
I: 0.84 to 1.01) as well as significant reductions in
ortality in the large ACOS, FAST-MI (French Regis-
ry on Acute ST-Elevation Myocardial Infarction) and
RACE (Global Registry of Acute Coronary Events)
egistries (10,24,27,28). The possible determinants for
he decreased mortality with enoxaparin are several: more
table and predictable anticoagulation, pleiotropic effects
f enoxaparin on markers such as von Willebrand factor
hat have been associated with mortality, and finally,
eduction of early major bleeding and ischemic events
hat have been shown to predict mortality (4 – 6,29,30).
Our findings should be interpreted in light of the non-
andomized comparison, despite the large number of pa-
ients enrolled, the formal and prospective nature of the
tudy, and the multivariable analyses performed to adjust for
otential confounders. Additionally, there was a significantmbalance in the proportion of patients treated with enoxapa-
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211in versus UFH in Western and Eastern Europe. In a sensi-
ivity analysis restricted to patients within Western Europe,
ortality rates through 90 days tended to be lower with
noxaparin (25 of 625 [4.0%] vs. 30 of 531 [5.7%], p 0.191).
imilarly, in Western Europe, 35 of 625 (5.6%) enoxaparin
atients versus 57 of 531 (10.7%) UFH patients experienced
eath, MI, urgent revascularization or refractory ischemia
hrough 30 days (p  0.0016). Other end points were more
imilar between groups.
The open-label use of the anticoagulant might be seen as
nother limitation, although each site selected the anticoag-
lant strategy they were comfortable with and used it in all
heir patients enrolled in the study. Also, patients in the
noxaparin group more frequently received at least 1 additional
ose of enoxaparin compared with the FINESSE main study
roup from 24 h after randomization through discharge/day 7
30.2% vs. 18.2%, p  0.001) and from discharge/day 7
hrough day 90 (11.2% vs. 4.1%, p 0.001). It is very difficult
o adjust for this, as a post-randomization event, in mod-
ling; and it might need to be viewed as part of the
reatment strategy difference that could have contributed to
he better outcomes observed. Finally, our results might
ave been influenced by the variations of the selected model
nd by any confounders we might have overlooked.
onclusions
indings from the enoxaparin substudy of the FINESSE
rial suggest that a strategy of intravenous enoxaparin over
FH was associated with a lower risk of both major TIMI
leeding and ischemic events in primary PCI of STEMI.
onfirmation from a randomized study, such as the cur-
ently recruiting ATOLL (Angioplasty and Intravenous
ovenox or Unfractionated Heparin) trial comparing intra-
enous enoxaparin (0.5 mg/kg) with intravenous UFH in
rimary PCI, is warranted.
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